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Signiﬁcant advances in our understanding of the genetic defects and the pathogenesis of juvenile myelomonocytic leukemia
(JMML) have been achieved in the last several years. The information gathered tremendously helps us in designing molecular
targeted therapies for this otherwise fatal disease. Various approaches are being investigated to target defective pathways/molecules
in this disease. However, eﬀective therapy is still lacking. Development of speciﬁc target-based drugs for JMML remains a big
challenge and represents a promising direction in this ﬁeld.
1. JuvenileMyelomonocytic Leukemia(JMML)
andCurrentClinicalStandardof Care
Juvenile myelomonocytic leukemia (JMML) is a rare hema-
tologic malignancy of early childhood with high mortality.
It represents 2% to 3% of all pediatric leukemias [1, 2],
and its incidence is approximately 0.6 per million children
per year [3]. Clinically, patients often present with pallor,
failure to thrive, decreased appetite, irritability, dry cough,
tachypnea, skin rashes, and diarrhea and are found to have
lymphadenopathy and hepatosplenomegaly on examination
[4–8]. JMML is characterized by leukocytosis with promi-
nent monocytosis, thrombocytopenia, elevation of fetal
hemoglobin (HbF), and hypersensitivity of hematopoietic
progenitors to granulocyte-macrophage colony-stimulating
factor (GM-CSF) [4–8].
Prior to the revision in 2008, JMML was diagnosed
based on the following criteria: presence of peripheral
blood monocytosis (>1000/μL); less than 20% blasts in the
bone marrow; absence of Philadelphia (Ph) chromosome or
BCR-ABL fusion gene AND at least two of the following
criteria: increased HbF levels; presence of immature myeloid
precursors in the peripheral blood; white blood cell count
>10,000/μL; GM-CSF hypersensitivity of myeloid progeni-
torsinvitro[5,9].In2008,theJMMLdiagnosticcriteriawere
revised to account for the molecular genetic abnormalities
that were identiﬁed in this disease [5].
The natural course of JMML is rapidly fatal with 80%
of patients surviving less than three years [10]. Low platelet
count, age at diagnosis older than 2 years, and high HbF
percentage have been shown to correlate with poor outcome
[11]. Allogeneic hematopoietic stem cell transplantation
(HSCT) is currently the only curative treatment for JMML,
but controversy exists in identifying the patients that need to
proceed to transplant immediately versus those that can be
observed for a longer time. Patients with Noonan syndrome
often develop a JMML-like myeloproliferative disorder that
may resolve spontaneously within one year of presenta-
tion [12]. While awaiting transplant, most patients receive
chemotherapy, and most clinicians will use cytarabine-based
acute myeloid leukemia-like therapy [10, 13]. Identiﬁcation
of gene mutations in the RAS-MAPK pathway has increased
interest in development of drugs that can speciﬁcally aﬀect
molecular targets. For more detailed review of genetic
mutations in JMML and approaches to therapy, please refer
to Dr. Loh’s recent article [14]. Here, we shall proceed to2 Advances in Hematology
Table 1: Summary of genetic mutations in JMML.
Gene Site of mutation Frequency
PTPN11 E76K, D61Y, D61V, E69K, A72T,
A72V, E76V/G/A, 35%
RAS
NRAS Codons 12 and 13
25% KRAS Codon 13
HRAS No mutation in codons 12, 13,
and 61 was found
NF1 Loss of wild-type NF1 allele 11–15%
CBL Codons 371, 380, 381, 384, 396,
398, 404, and 408. 17%
Splice sites 1227, 1228, and 1096
brieﬂy discuss molecular defects in JMML with focus on
potential drug targets.
2. Identiﬁcation of GeneticMutations in JMML
The molecular defects in JMML result in deregulated signal-
ing through the RAS pathway [15–17]. These mutations are
mutuallyexclusivewhichhighlightsthemajorfunctionalrole
oftheRASpathwayactivationinJMMLpathophysiologyand
disease progression. The speciﬁc genes implicated in JMML
are summarized in Table 1.
2.1. PTPN11. Somatic mutations within PTPN11,w h i c h
encodes protein tyrosine phosphatase SHP-2, have been
found in 35% of JMML patients [18, 19]. PTPN11 mutations
were also associated with poor prognosis for survival.
Mutation in PTPN11 was the only unfavorable factor for
relapse after hematopoietic stem cell transplantation [20].
SHP-2 contains 2 Src homology 2 domains (N-SH2 and C-
SH2) at the amino terminus and a phosphatase domain at
the carboxy terminus [21–25]. It is involved in a variety of
signaling pathways, especially the RAS/MAPK/ERK pathway
[26–28]. SHP-2 is normally self-inhibited by hydrogen
bonding of the backside of the N-SH2 domain loop to
the deep pocket of the PTP domain [29, 30]. The self-
inhibition leads to occlusion of the phosphatase catalytic site
and a distortion of the pY-binding site of N-SH2. PTPN11
mutations found in JMML are mainly localized in the N-
SH2 domain. These mutations result in amino acid changes
at the interface formed between N-SH2 and PTP domains,
disrupting the inhibitory intramolecular interaction, leading
to hyperactivation of SHP-2 catalytic activity [18, 31]. In
addition, disease mutations enhance the binding of mutant
SHP-2 to signaling partners [32–34]. Recent studies have
shown that PTPN11 gain-of-function mutations induce
cytokine hypersensitivity in myeloid progenitors [16, 34,
35] and myeloproliferative disease with some similarity to
JMML in mice [32, 36–38], establishing the causal role
of PTPN11 mutations in the pathogenesis of JMML. It is
evident that increased signal transduction along SHP-2’s
pathways leads to aberrant hematopoietic cell proliferation
and diﬀerentiation. SHP-2 may, thus, be an ideal target of
mechanism-based therapeutics for this disease.
2.2. RAS. The RAS subfamily includes three members:
HRAS, KRAS,a n dNRAS. Twenty-ﬁve percent of JMML
patients were found to have a somatic NRAS or KRAS point
mutation [20, 39]. Flotho et al. analyzed 36 children with
JMML.RASmutationsweredetectedin6cases.Twochildren
had a mutation in codon 12 of NRAS, 3 children in codon 13
of NRAS, and 1 child in codon 13 of KRAS.N om u t a t i o ni n
HRAS codons 12, 13, or 61 was found [40]. De Filippi et al.
reported a 38G > A (G13D) mutation in the NRAS gene in
all types of cells checked in a male infant who was diagnosed
with JMML [41]. This case suggests that constitutively active
mutations of NRAS may be responsible for the development
of JMML in children [41].
2.3. NF1. In 1994, Shannon et al. demonstrated loss of the
wild-type NF1 allele in the diseased bone marrow of children
with JMML aﬀected by neuroﬁbromatosis type 1 (NF1) [42].
The protein product of NF1, neuroﬁbromin (NF1), contains
a GTPase-activating protein- (GAP-) related domain. It
inhibits RAS signaling by increasing the intrinsic GTPase
activity of RAS-GTP and, thus, the generation of inactive
RAS-GDP [43]. Eleven percent of JMML patients have
constitutiveNF1[44]and15%oftheJMMLpatientswithout
clinical signs of NF1 [39, 45]. A mitotic recombination event
in JMML-initiating cells led to 17q uniparental disomy with
homozygous loss of normal NF1, providing conﬁrmatory
evidence that the NF1 gene is crucial for the increased
incidence of JMML in NF1 patients [44]. In addition,
children (but not adults) with NF1 show a 200- to 500-
fold increase in the incidence of de novo malignant myeloid
disorders, particularly JMML [46].
2.4. CBL. The Casitas B-cell lymphoma (CBL, c-CBL)
proteinisamemberoftheCBLfamilyofE3ubiquitinligases.
Loh et al. ﬁrst reported that c-CBL mutations were detected
in 27 of 159 JMML samples, and 13 of these mutations
alter codon Y371 [47]. The same c-CBL mutation was also
found in another study with a smaller cohort of JMML
patients [48]. A recent study screened CBL mutations inAdvances in Hematology 3
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65 patients with JMML [49] .Ah o m o z y g o u sm u t a t i o no f
CBL was found in leukemic cells of 4/65 (6%) patients. A
heterozygous germ line CBL Y371H substitution was found
in each of them and was inherited from the father in one
patient. The germ line mutation represents the ﬁrst hit, with
somatic loss of heterozygosity being the second hit positively
selected in JMML cells [49]. Individuals with germ line CBL
mutations are at increased risk of developing JMML, which
might follow an aggressive clinical course or resolve without
treatment [50].
In addition to PTPN11, RAS,a n dNF1 mutations, other
mutations have been reported to occur rarely in JMML,
such as additional sex combs like 1 (AXSL1)[ 51]a n df m s -
like tyrosine kinase 3 (FLT3) [52]. Mutations in let-7 or in
binding sites of let-7 mRNA targets lead to an upregulation
of RAS genes in JMML. It is possible that other microRNAs
knowntobindtoNRAS-orKRAS-UTR,orotherlet-7family
mi-RNAs may play a role in the development of JMML
[53]. However, mutations which are reported to play a major
role in myeloproliferative neoplasms, such as ten-eleven
translocation-2 (TET2), runt-related transcription factor 1
isoform (RUNX1), janus kinase 2 (JAK2) V617F [54], and
Soc-2 suppressor of clear homolog SHOC2 [55]a r en o t
involved in JMML.
3. Chromosomal Aberrations
Some chromosome abnormalities were found in JMML.
The most common chromosome abnormalities in JMML
patients are monosomy 7 or deletion 7q (-7/del(7q)) [56]. In
addition, there are some case reports for other chromosomal
aberrations. For example, a 11-month-old boy with JMML
had deletion 5q as the sole clonal chromosome abnormality
[57]. Another JMML patient had a chromosomal transloca-
tion at t(1;5) [58]. Also, leukemic cells in a JMML patient
harboreda46,XX,der(12)t(3;12)(q21∼22;p13.33)karyotype
and subsequently developed partial trisomy of 3q [59].
However, at this time speciﬁc genes associated with these
breakpoints are not yet identiﬁed, and; thus, the relevance of
these chromosomal aberrations remains to be determined.
4. Recent Experimental Therapy for JMML
The recent focus in JMML has concentrated on using the
information gained from knowledge of these molecular
defects in order to design targeted drug therapy. Animal
models, especially mouse models of the disease, are com-
monly used to test molecularly targeted agents. Since RAS
hyperactivation is very important in the pathophysiology of
JMML, agents designed to decrease RAS activity are being
evaluated. There are numerous approaches that have been
tested to target this pathway (Figure 1).
4.1. RAF1 Enzyme. RAF1 is a MAP kinase (MAP3K) that
functions downstream of the RAS subfamily of membrane-
associated GTPases to which it binds directly and plays
an important role in the MAPK/ERK signal transduction
pathway as part of a protein kinase cascade. A DNA enzyme
designedtospeciﬁcallycleavemRNAforRAF1,namedRAF1
enzyme, was tested on JMML cells cultured both in vitro and
inaxenograftmodelofJMML.Whenimmunodeﬁcientmice
engrafted with JMML cells were treated continuously with
this enzyme for 4 weeks, JMML cell numbers in the recipient
murine bone marrows were profoundly reduced. No eﬀect
of the enzyme on the proliferation of normal bone marrow
cellswasfoundinvitro,indicatingitsspeciﬁcityandpotential
safety [60].4 Advances in Hematology
4.2. RAF1 Inhibitor: BAY 43-9006. BAY 43-9006 is a low-
molecular-weight agent that inhibits both the wild-type
BRAF and the activated V599E mutant BRAF by binding at
the active site of the kinase [61]. BAY 43-9006 can signif-
icantly inhibit tumor growth in a dose-dependent manner
and has demonstrated oral in vivo activity in three human
tumor xenograft models with mutant KRAS genes (HCT116,
MiaPaca-2, H460)a n do n eh u m a nt u m o rx e n o g r a f tw i t h
a wild-type KRAS but exhibiting overexpression of growth
factor receptors for epidermal growth factor (EGF) and HER
2( S K O V - 3 )[ 62]. Based on these ﬁndings, a phase II window
clinical trial is under development to evaluate response rate
and acute toxicity to JMML patients [5].
4.3. Farnesyltransferase Inhibitor (FTI). RAS is ﬁrst activated
at the cell membrane via the addition of a farnesyl group to
the newly translated protein. Farnesyltransferase inhibitors
(FTIs) can prevent RAS translocation to the plasma mem-
brane, thus, leading to downregulation of RAS-activated
cellular pathways, so its competitive inhibitors have been
developed as a novel class of anticancer therapeutics. L-
744,832 is one such farnesyltransferase inhibitor. It can
inhibit HRAS prenylation in cell lines and in primary
hematopoietic cells, abolish the in vitro growth of myeloid
progenitor colonies in response to GM-CSF, and increase
the amount of unprocessed HRAS in bone marrow cells.
However, FTIs had no detectable eﬀect on NRAS, and the
mousemodelwithJMMLfeaturescreatedbytransplantation
of Nf1−/− fetal liver cells did not respond to L-744,832
treatment [63]. L-739,749, another kind of FTI, also has
signiﬁcant growth inhibitory eﬀects in vitro, indicating a
potentialtreatmentforJMML[64].Unfortunately,FTIshave
modest to little activity in clinical trials when used as a single
agent to treat cancers, yet recent studies show that when
combined with other inhibitors, such as AKT inhibitors,
FTIs do show a therapeutic potential in some cancer models
[65, 66].
4.4. SHP-2 Phosphatase Inhibitor. The direct connection
between activating mutations in PTPN11 and JMML indi-
cates that SHP-2 may be a useful target for mechanism-
based therapeutics for this disease. It is very important
to develop selective SHP-2 inhibitors. The availability of
SHP-2-speciﬁc inhibitors could lead to the development of
new drugs that would ultimately serve as treatments for
JMML. However, development of selective SHP-2 inhibitors
has been challenging as the catalytic site of SHP-2 shares a
high homology with those of other tyrosine phosphatases,
especially SHP-1 that plays a negative role in cytokine
signaling in contrast to SHP-2 phosphatase [26–28]. Several
groups have attempted to identify low molecular weight
inhibitors for SHP-2 phosphatase using various approaches
[67–70]. However, the inhibitors identiﬁed to date either
show low or no selectivity between SHP-2 and highly related
SHP-1 phosphatase. Furthermore, therapeutic eﬀects of
these inhibitors in mouse models or human JMML samples
have yet to be determined. More eﬀorts are still needed to
advance this line of research.
4.5. GM-CSF Antagonist: E21R. GM-CSF markedly pro-
motes proliferation and survival of JMML cells and, thus,
contributes to the aggressive nature of this malignancy
[71]. Iversen et al. developed a GM-CSF analogue (E21R)
that carries a single point mutation at position 21 in
which glutamic acid is substituted for arginine [72]. It can
eﬀectively antagonize GM-CSF in binding experiments and
in functional assays. They administrated E21R or isotonic
saline to SCID/NOD mice transplanted by JMML cells or
normal bone marrow cells and found that E21R reduced
growth of JMML cell load in the mouse bone marrow [8].
As TNFα may increase the production of GM-CSF [71],
E21R also synergizes with anti-TNFα monoclonal antibody
(MoAb) cA2 in suppressing JMML cell growth. Remarkably,
E21R preferentially eliminated leukemic cells [8]. These data
suggestthatE21RmayhaveatherapeuticpotentialinJMML.
4.6. Inhibition of Angiogenesis. Angiogenesis is essential for
growth and metastasis of solid tumors and probably also
for hematological malignancies. Endostatin and PI-88, two
kinds of angiogenic inhibitors, were used to treat JMML
xenograft mice and resulted in a reduction of about 95%
of the malignant cell load. Furthermore, it was evident that
neither endostatin nor PI-88 interfered with the engraftment
of normal cells [73].
4.7. STAT5 Activation by the RAS/RAF/MEK/ERK Pathway
in JMML-Biomarker and Potential Therapeutic Target. In
addition to activation of the RAS pathway in JMML, there
are several studies that have also shown enhanced signal
transducer and activator of transcription 5 (STAT5) activa-
tion downstream of activated RAS. In a KRAS G12D mouse
model, STAT5 activation was also associated with ERK and
S6K phosphorylation [74]. KRAS also led to hyper-active
STAT5, AKT, and ERK pathways [75]. Furthermore, NRAS
causedanadultCMML-likephenotypecharacterizedbyERK
and STAT5 activation via a GM-CSF-dependent induction
mechanism [76]. In patient samples, Kotecha et al. [77]
elegantly showed that both ERK and STAT5 activation are
associated with human JMML, but, interestingly, it was the
phosphorylated STAT5 that was prognostic in these patients,
suggesting that eﬀective suppression of STAT5 will also be an
important biomarker in JMML-oriented targeted therapies.
Therefore, monitoring pSTAT5 by phospho-ﬂow cytometry
shows promise for clinical application. Additionally, STAT5
can partner with the adapter protein GAB2 to provoke
activation of the PI3-kinase pathway [78]. Interestingly,
GAB2 is also a major partner of oncogenic SHP-2 with
gain-of-function mutation D61G and is responsible for a
signiﬁcant contribution to the myeloproliferative disease
phenotype in mice [38].
5.DiscussionsandPerspectives
The clinical therapy of JMML has signiﬁcantly improved
over the last 20 years. However, the low incidence of
the disease has limited the capacity to perform large-scale
pathophysiological studies and testing newer therapeuticAdvances in Hematology 5
strategies. JMML is a disease that only occurs in children,
and drug dosage modiﬁcations are needed in children as
compared to adults. All these factors limit the development
ofJMMLtreatmenttosomeextent.Speciﬁcinhibitorsforthe
molecular targets identiﬁed in this disease are still lacking.
Molecular mechanisms of JMML have been elucidated
in almost 85% of patients, but it is also true that a few
JMML patients with Noonan syndrome can spontaneously
recover without intervention [79, 80]. This means that we
do not completely understand this disease, and there is
much more to learn. It is indeed promising that there
have been some novel agents evaluated in investigational
phase II trials of JMML patients [81, 82], and there is
legitimate hope that the knowledge we have gained about
JMML will soon translate into more eﬃcacious treatment
modalities. Scientists and clinicians should continue to study
molecular defects in JMML in a concerted eﬀort to deﬁne
novel therapeutic targets and to develop eﬀective, less toxic,
therapeutic interventions.
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